AB049. P-17. A phase II study of HDAC inhibition to sensitize to immunotherapy in advanced cholangiocarcinoma

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have unlocked the promise of modulating the immune tumor microenvironment (TME) in the battle against cancer, but it remains unclear whether they might be useful for cholangiocarcinoma (CCA). Our laboratory has explored entinostat, a histone deacetylase inhibitor (HDACi) to alter the function of suppressive myeloid derived suppressor cells (MDSC) in favor of recruiting T cells in murine pancreatic ductal adenocarcinoma (PDAC) models, showing improved survival when given with anti-PD1 therapy. We hypothesize that the HDACi entinostat may prime an ICI-insensitive cancer into a more sensitive one.

Methods

An open-label, two-arm study enrolling patients with histologically confirmed advanced CCA or PDAC, who have progressed after

SUBMITTER:  

PROVIDER: S-EPMC6421164 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature